Beyond PSA: a multi-modal pilot study identifying novel proteomic biomarkers in paraffin-embedded prostate cancer tissue

1 Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. DOI: 10.3322/caac.21834 Search in Google Scholar

2 Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24-38. DOI: 10.1038/s41391-018-0079-0 Search in Google Scholar

3 Shiner A, Sperandio RC, Naimi M, Emmenegger U. Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies. J Clin Med. 2024;13(3). DOI: 10.3390/jcm13030734 Search in Google Scholar

4 Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019;6(2):129-36. DOI: 10.1016/j.ajur.2018.11.007 Search in Google Scholar

5 Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022;20(1):1-11. DOI: 10.1186/s12916-021-02230-y Search in Google Scholar

6 Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. DOI: 10.1056/NEJMoa031918 Search in Google Scholar

7 Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst - Monogr. 2012;2011(45):146-51. DOI: 10.1093/jncimonographs/lgs031 Search in Google Scholar

8 Dunne JC, Lamb DS, Delahunt B, Murray J, Bethwaite P, Ferguson P, et al. Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. Clin Proteomics. 2015;12(1). DOI: 10.1186/s12014-015-9096-3 Search in Google Scholar

9 Gao Y, Wang YT, Chen Y, Wang H, Young D, Shi T, et al. Proteomic tissue-based classifier for early prediction of prostate cancer progression. Cancers (Basel). 2020;12(5):1-21. DOI: 10.3390/cancers12051268 Search in Google Scholar

10 Bărar AA, Pralea IE, Maslyennikov Y, Munteanu R, Berindan-Neagoe I, Pîrlog R, et al. Minimal Change Disease: Pathogenetic Insights from Glomerular Proteomics. Int J Mol Sci. 2024 May 21;25(11):5613. DOI: 10.3390/ijms25115613 Search in Google Scholar

11 Bărar AA, Pralea IE, Berindan-Neagoe I, Pirlog R, Nutu A, Maslyennikov Y, et al. Proteomic patterns in glomerular research, a laser capture microdissection and liquid chromatography-tandem mass spectrometry approach. Rev Rom Med Lab. 2023 Oct 1;31(4):263-74. DOI: 10.2478/rrlm-2023-0029 Search in Google Scholar

12 Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17(8):1735-61. DOI: 10.1038/s41596-022-00710-w Search in Google Scholar

13 Xie Z, Bailey A, Kuleshov M V., Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1(3):1-84. DOI: 10.1002/cpz1.90 Search in Google Scholar

14 Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science (80- ). 2015;347(6220). DOI: 10.1126/science.1260419 Search in Google Scholar

15 Hernández J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894-904. DOI: 10.1002/cncr.20480 Search in Google Scholar

16 Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006;98(19):1420-4. DOI: 10.1093/jnci/djj378 Search in Google Scholar

17 Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol. 2017;28(8):1903-9. DOI: 10.1093/annonc/mdx247 Search in Google Scholar

18 Eguchi T, Sogawa C, Ono K, Matsumoto M, Tran MT. Cell Stress Induced Stressome Release Including. Cells. 2020;9(755). DOI: 10.3390/cells9030755 Search in Google Scholar

19 Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: At the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):1-47. DOI: 10.3390/ijms21124507 Search in Google Scholar

20 Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, et al. Glucose metabolism in the progression of prostate cancer. Front Physiol. 2017;8(FEB). DOI: 10.3389/fphys.2017.00097 Search in Google Scholar

21 Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004;3:1-13. DOI: 10.1186/1476-4598-3-29 Search in Google Scholar

22 Pircher A, Schäfer G, Eigentler A, Pichler R, Puhr M, Steiner E, et al. Robo 4-the double-edged sword in prostate cancer: Impact on cancer cell aggressiveness and tumor vasculature. Int J Med Sci. 2019;16(1):115-24. DOI: 10.7150/ijms.28735 Search in Google Scholar

23 Habrowska-Górczyńska DE, Kozieł MJ, Kowalska K, Piastowska-Ciesielska AW. FOXO3a and its regulators in prostate cancer. Int J Mol Sci. 2021;22(22). DOI: 10.3390/ijms222212530 Search in Google Scholar

24 Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, et al. Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling. Eur J Cancer. 2022;174(6611):S4-5. DOI: 10.1016/S0959-8049(22)00818-8 Search in Google Scholar

25 Hoshi S, Meguro S, Imai H, Matsuoka Y, Yoshida Y, Onagi A, et al. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci. 2021;112(5):1899-910. DOI: 10.1111/cas.14865 Search in Google Scholar

26 Bonaterra GA, Schleper A, Skowronek M, Kilian LS, Rink T, Schwarzbach H, et al. Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia. Cancers (Basel). 2022;14(19). DOI: 10.3390/cancers14194591 Search in Google Scholar

27 Mahon KL, Sutherland SIM, Lin HM, Stockler MR, Gurney H, Mallesara G, et al. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. Prostate. 2024;84(8):747-55. DOI: 10.1002/pros.24691 Search in Google Scholar

28 Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells. J Immunol. 2006;177(12):8730-9. DOI: 10.4049/jimmunol.177.12.8730 Search in Google Scholar

29 Meyer-Siegler KL, Bellino MA, Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002 Mar 11;94(5):1449-56. DOI: 10.1002/cncr.10354 Search in Google Scholar

30 Muramaki M, Miyake H, Yamada Y, Hara I. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep. 2006 Jan 1;253-7. DOI: 10.3892/or.15.1.253 Search in Google Scholar

31 Tekin B, Dasari S, Theis JD, Vrana JA, Murray DL, Oglesbee D, et al. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15. Hum Pathol. 2023;135:35-44. DOI: 10.1016/j.humpath.2023.03.001 Search in Google Scholar

32 Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory fator expression in prostate cancer. BMC Cancer. 2005;5:1-12. Available from: DOI: 10.1186/1471-2407-5-73 DOI: 10.1186/1471-2407-5-73 Search in Google Scholar

33 Zhou B, Ren C, Zu L, Zheng L, Guo L, Gao W. Elevated plasma migration inhibitory factor in hypertension-hyperlipidemia patients correlates with impaired endothelial function. Medicine (Baltimore). 2016 Oct;95(43):e5207. DOI: 10.1097/MD.0000000000005207 Search in Google Scholar

34 Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, et al. Association of Systemic Concentrations of Macrophage Migration Inhibitory Factor With Impaired Glucose Tolerance and Type 2 Diabetes. Diabetes Care. 2006 Feb 1;29(2):368-71. DOI: 10.2337/diacare.29.02.06.dc05-1474 Search in Google Scholar

35 Sarkar S, Legere S, Haidl I, Marshall J, Macleod JB, Aguiar C, et al. Serum GDF15, a promising biomarker in obese patients undergoing heart surgery. Front Cardiovasc Med. 2020;7(June). DOI: 10.3389/fcvm.2020.00103 Search in Google Scholar

36 Bansal N, Kumar D, Gupta A, Chandra D, Sankhwar SN, Mandhani A. Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation. Sci Rep. 2017 Dec 4;7(1):16824. DOI: 10.1038/s41598-017-17207-2 Search in Google Scholar

37 Song H, Shen Q, Hu S, Jin J. The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling. Biol Open. 2020;9(11):1-7. DOI: 10.1242/bio.053447 Search in Google Scholar

38 Sörensen-Zender I, Beneke J, Schmidt BM, Menne J, Haller H, Schmitt R. Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol. 2013;14(1):1-6. DOI: 10.1186/1471-2369-14-145 Search in Google Scholar

39 Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6):1265-72. DOI: 10.1093/carcin/bgt056 Search in Google Scholar